Proteins specific for pyoverdine and pyochelin

US10329334B2 · kind B2 · utility

Assignee

• Sanofi · FR

Inventors

• Carsten Corvey · Frankfurt am Main, DE
• Heike Stump · Karben, DE
• Jochen Kruip · Frankfurt am Main, DE
• Bernhard Calandra · Chilly-Mazarin, FR
• Astrid Rey · Paris, FR
• Nathalie Karst · Vitry-sur-Seine, FR
• Michael Mourez · Toulouse, FR
• Laurent Fraisse · Toulouse, FR
• Christine Rothe · Freising, DE
• Andrea Allersdorfer · Wolnzach, DE
• Alexander Wiedenmann · Ulm, DE
• Marlon Hinner · Freising, DE
• Bradley M. Lunde · Lebanon, US
• Kristian Jensen · Munich, DE
• Martin Hülsmeyer · Römerberg, DE

Key dates

• Filing date: Nov 16, 2017
• Grant date: Jun 25, 2019
• Expiry date: Nov 16, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K14/47
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides hNGAL muteins that bind a pyoverdine family member or pyochelin and can be used in various application including pharmaceutical applications, for example, to inhibit or reduce growth of P. aeruginosa. The present disclosure also concerns methods of making one or more pyoverdine- or pyochelin-binding muteins described herein as well as compositions comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions comprising one or more of such muteins.